Manufacturing · Profile from Manufacturing Research Companion: Companies, Strategic Moves, and Technical Studies
Becton Dickinson
The Franklin Lakes, New Jersey maker of syringes, needles, IV catheters, infusion pumps, medication-dispensing cabinets and surgical and interventional devices — by volume one of the largest medical-device manufacturers in the world, producing billions of disposable units a year (company claim, verify scale). Its manufacturing story turns on a quality-system failure that took a flagship product off the market for years. BD bought CareFusion in 2015 (~$12.2bn) for the Alaris infusion pump and the Pyxis dispensing cabinet. Alaris was already operating under an FDA consent decree that dated from 2007. In 2020 BD stopped shipping new Alaris pumps (from memory for the date, verify), and they returned only after a new 510(k) clearance on 21 Jul 2023. Remediating the US installed base then took years, and its end is expected to cost ~200 bps of revenue growth in FY2027 (company, Aug 2026). Around that episode BD also bought C. R. Bard (2017, ~$24bn, verify), spun off its diabetes-injection business as Embecta (2022, verify) and, in Feb 2026, combined its Biosciences and Diagnostic Solutions businesses with Waters Corporation, becoming a "pure-play" medtech company. A disposables giant has to run two kinds of manufacturing at once: very high-volume moulding and assembly, and the software-driven design control of a networked device.
At a glance
- Founded
- 1897 by Maxwell W. Becton and Fairleigh S. Dickinson (from memory, verify)
- Headquarters
- Franklin Lakes, New Jersey
- Ownership / structure
- Public (NYSE: BDX)
- Leadership (2026)
- Tom Polen, chairman, CEO and president (named in the FY2025 release; CEO since 2020, from memory, verify)
- Segments (FY2026, after Waters)
- Medical Essentials, Connected Care (Alaris, Pyxis), BioPharma Systems (prefillable syringes) and Interventional (ex-Bard) — "new BD" structure (from memory for the labels, verify)
- Scale
- Q3 FY2026 (quarter to 30 Jun 2026; release 6 Aug 2026): revenue ~$5.0bn (+5.4% reported, +4.4% FX-neutral); GAAP diluted EPS from continuing operations $1.64, adjusted $3.23; FY2026 adjusted EPS guidance raised to $12.62–12.72 (continuing operations, post-Waters basis); tariffs ~110 bps of headwind in the quarter; ~8% gross plant productivity (company and call coverage). FY2026 Q4 results were scheduled for 5 Nov 2026 and were not seen by this batch
- Plants (US, selected)
- Large US disposables plants in Nebraska (Columbus, Holdrege, Broken Bow), Connecticut (Canaan), Utah, North Carolina and elsewhere (from memory, verify); Alaris manufacturing under CareFusion 303 (San Diego, from memory, verify); a large international network incl. Mexico, Ireland, Singapore and China (from memory, verify)
- Signature moves (incl. failures)
- Founding and the syringe business (1897–); safety-engineered sharps and the Needlestick Safety and Prevention Act (2000); CareFusion and Alaris (2015); Bard (2017); the Alaris shipment halt and the 2023 clearance (2020–23, failure); the Embecta spin-off (2022); tariffs, plant consolidation and the Pyxis warning letter (2024–26); the Waters combination (Feb 2026)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1897
Founding and the Syringe Business
Founding / product and process (from reusable glass syringes to sterile single-use plastic syringes and needles)
2000
Safety Syringes and the Needlestick Act
Product and line conversion (safety-engineered sharps) driven by regulation
2015
CareFusion and Alaris
Acquisition (medication management: Alaris infusion pumps, Pyxis dispensing cabinets, respiratory and infection-prevention products)
2017
Bard Acquisition
Acquisition (interventional devices: vascular, urology, oncology access, surgical and hernia products)
2020
Alaris Shipment Halt and the 2023 Clearance
Quality failure and regulatory action (consent decree, shipment halt, new 510(k)), then remediation and return to market
2022
Embecta Diabetes Spin Off
Spin-off (diabetes-care injection devices: pen needles, insulin syringes, safety devices)
2025
Tariffs Plant Consolidation and the Pyxis Warning Letter
Footprint consolidation and productivity programme under tariff pressure, alongside a regulatory action (FDA warning letter)
2026
Waters Biosciences and Diagnostics Combination
Divestment by Reverse Morris Trust (Biosciences and Diagnostic Solutions spun off and merged into a Waters subsidiary)